Pulmonary vascular remodeling in congenital cardiovascular abnormalities: an eternal topic.
- Author:
Han-Min LIU
1
Author Information
1. Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu 610041, China. muxuan@163.net.
- Publication Type:Journal Article
- MeSH:
DNA Damage;
Familial Primary Pulmonary Hypertension;
Heart Defects, Congenital;
genetics;
pathology;
Humans;
Hypertension, Pulmonary;
pathology;
Muscle, Smooth, Vascular;
pathology;
Paclitaxel;
pharmacology
- From:
Chinese Journal of Contemporary Pediatrics
2013;15(10):805-809
- CountryChina
- Language:Chinese
-
Abstract:
Pulmonary arterial hypertension (PAH) is one of the most severe complications of congenital heart defects with left to right shunt. Pulmonary vascular remodeling (PVR) is extremely essential in PAH. Therefore, prevention and reversion of PVR is one of the most important factors for improving quality of life for children suffering from PAH. In this article we reviewed the emerging research views on PVR from the disciplines of oncology and anti-tumor pharmacy. Two main sections were included. On the one hand, we introduced the "ATM signal turning point hypothesis" from the DNA damage response (DDR) mechanism research in oncology. The hypothesis suggests that the tumor-like proliferation of vascular smooth muscle cells might be the pathological basis of obstructive PAH. On the other hand, a new lung-targeted drug delivery system based on the fact that low concentration of anti-tumor drugs can inhibit angiogenesis without cellular toxicity was introduced. These new research directions could extend current practice in PVR therapy.
